Phase-I trial of survivin inhibition with EZN3042 in dogs with spontaneous lymphoma
Phase-I trial of survivin inhibition with EZN3042 in dogs with spontaneous lymphoma
Lymphoma is a common cancer in dogs. While most dogs receiving chemotherapy experience remission, very few are cured, and median survival times are generally in the 12-month range. Novel approaches to treatment are unquestionably needed.